FR2450608A1 - Agent carcinostatique et immunostimulant contenant un lysophospholipide et un phospholipide et procede pour le preparer - Google Patents

Agent carcinostatique et immunostimulant contenant un lysophospholipide et un phospholipide et procede pour le preparer

Info

Publication number
FR2450608A1
FR2450608A1 FR8004736A FR8004736A FR2450608A1 FR 2450608 A1 FR2450608 A1 FR 2450608A1 FR 8004736 A FR8004736 A FR 8004736A FR 8004736 A FR8004736 A FR 8004736A FR 2450608 A1 FR2450608 A1 FR 2450608A1
Authority
FR
France
Prior art keywords
lysophospholipid
carcinostatic
phospholipide
preparing
same
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
FR8004736A
Other languages
English (en)
Other versions
FR2450608B1 (fr
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Toyama Chemical Co Ltd
Original Assignee
Toyama Chemical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from JP2460079A external-priority patent/JPS55118419A/ja
Priority claimed from JP11726279A external-priority patent/JPS5840929B2/ja
Application filed by Toyama Chemical Co Ltd filed Critical Toyama Chemical Co Ltd
Publication of FR2450608A1 publication Critical patent/FR2450608A1/fr
Application granted granted Critical
Publication of FR2450608B1 publication Critical patent/FR2450608B1/fr
Granted legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

NOUVELLE COMPOSITION UTILE NOTAMMENT COMME AGENT CARCINOSTATIQUE ET IMMUNOSTIMULANT. ELLE SE CARACTERISE EN CE QU'ELLE COMPREND UN LYSOPHOSPHOLIPIDE ET UN PHOSPHOLIPIDE. APPLICATION THERAPEUTIQUE.
FR8004736A 1979-03-05 1980-03-03 Agent carcinostatique et immunostimulant contenant un lysophospholipide et un phospholipide et procede pour le preparer Granted FR2450608A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2460079A JPS55118419A (en) 1979-03-05 1979-03-05 Antihemolytic composition consisting of fat emulsion and immunizator and carcinostatic agent containing the same
JP11726279A JPS5840929B2 (ja) 1979-09-14 1979-09-14 リゾレシチンおよびリン脂質を含有する制癌剤およびその製造法

Publications (2)

Publication Number Publication Date
FR2450608A1 true FR2450608A1 (fr) 1980-10-03
FR2450608B1 FR2450608B1 (fr) 1984-12-21

Family

ID=26362150

Family Applications (1)

Application Number Title Priority Date Filing Date
FR8004736A Granted FR2450608A1 (fr) 1979-03-05 1980-03-03 Agent carcinostatique et immunostimulant contenant un lysophospholipide et un phospholipide et procede pour le preparer

Country Status (8)

Country Link
US (1) US4372949A (fr)
CA (1) CA1145260A (fr)
DE (1) DE3008082A1 (fr)
FR (1) FR2450608A1 (fr)
GB (1) GB2046092B (fr)
IT (1) IT1145357B (fr)
NL (1) NL8001292A (fr)
SE (1) SE459228B (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2519864A1 (fr) * 1982-01-20 1983-07-22 Yamanouchi Pharma Co Ltd Composition huileuse a base de medicaments antitumoraux
EP0236487A1 (fr) * 1985-09-17 1987-09-16 Yeda Research And Development Company, Ltd. Inactivation d'un virus
EP0370457A1 (fr) * 1988-11-23 1990-05-30 Abbott Laboratories Emulsion de lipides pour traitement du SIDA
WO1994003180A1 (fr) * 1992-07-30 1994-02-17 Prime European Therapeuticals S.P.A. Derives glycerophospho a activite pharmacologique

Families Citing this family (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3127503A1 (de) * 1981-07-11 1983-02-17 Boehringer Mannheim Gmbh, 6800 Mannheim Neue phospholipide, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
IL63734A (en) * 1981-09-04 1985-07-31 Yeda Res & Dev Lipid fraction,its preparation and pharmaceutical compositions containing same
US4452747A (en) * 1982-03-22 1984-06-05 Klaus Gersonde Method of and arrangement for producing lipid vesicles
US5334583A (en) * 1982-07-23 1994-08-02 Ciba-Geigy Corp. Use of sugar derivatives for the prophylaxis and treatment of virus infections
US5189017A (en) * 1982-07-23 1993-02-23 Ciba-Geigy Corporation Use of sugar derivatives for the prophylaxis and treatment of virus infections
US5059591B1 (en) * 1983-05-26 2000-04-25 Liposome Co Inc Drug preparations of reduced toxicity
CA1237670A (fr) * 1983-05-26 1988-06-07 Andrew S. Janoff Reduction de la toxicite de certains medicaments
US4649155A (en) * 1983-07-22 1987-03-10 Hoffmann-La Roche Inc. Injectable solutions
JPS6045518A (ja) * 1983-08-22 1985-03-12 Takeda Chem Ind Ltd 抗シヨツク剤
US4873088A (en) * 1983-09-06 1989-10-10 Liposome Technology, Inc. Liposome drug delivery method and composition
JPS6081193A (ja) * 1983-10-11 1985-05-09 Takeda Chem Ind Ltd リン脂質
JPS60208910A (ja) * 1984-03-31 1985-10-21 Green Cross Corp:The 水難溶性薬物・リン脂質複合体の製造方法
PT78628B (en) * 1984-05-02 1986-06-18 Liposome Co Inc Pharmaceutical composition with reduced toxicity
DE3421468A1 (de) * 1984-06-08 1985-12-19 Dr. Rentschler Arzneimittel Gmbh & Co, 7958 Laupheim Lipidnanopellets als traegersystem fuer arzneimittel zur peroralen anwendung
DE3572491D1 (en) * 1984-07-25 1989-09-28 Ciba Geigy Ag Phosphatidyl compounds, process for their preparation and their use
US5077056A (en) * 1984-08-08 1991-12-31 The Liposome Company, Inc. Encapsulation of antineoplastic agents in liposomes
US5736155A (en) * 1984-08-08 1998-04-07 The Liposome Company, Inc. Encapsulation of antineoplastic agents in liposomes
US4921706A (en) * 1984-11-20 1990-05-01 Massachusetts Institute Of Technology Unilamellar lipid vesicles and method for their formation
US4622188A (en) * 1984-12-21 1986-11-11 E. I. Du Pont De Nemours And Company Method for manufacturing liposomes
US4737276A (en) * 1984-12-21 1988-04-12 E. I. Du Pont De Nemours And Company Apparatus for manufacturing liposomes
US5409704A (en) * 1985-06-26 1995-04-25 The Liposome Company, Inc. Liposomes comprising aminoglycoside phosphates and methods of production and use
US4916249A (en) * 1985-07-03 1990-04-10 Hans Brachwitz Glycero-3(2)-phospho-L-serine derivatives and salts thereof
DE3683487D1 (de) * 1985-10-21 1992-02-27 Liposome Co Inc In situ-herstellung und verabreichung von liposomen.
US4923854A (en) * 1986-01-22 1990-05-08 The Liposome Company, Inc. Solubilization of hydrophobic materials using lysophospholipid
US4873322A (en) * 1986-01-24 1989-10-10 Ciba-Geigy Corporation Saccharide derivatives and processes for their manufacture
US4737323A (en) * 1986-02-13 1988-04-12 Liposome Technology, Inc. Liposome extrusion method
US4971801A (en) * 1986-06-09 1990-11-20 Cell Technology, Inc. Biologic response modifier
US5009956A (en) * 1987-02-24 1991-04-23 Univ Minnesota Phospholipase A2-resistant liposomes
MX9203808A (es) * 1987-03-05 1992-07-01 Liposome Co Inc Formulaciones de alto contenido de medicamento: lipido, de agentes liposomicos-antineoplasticos.
US6406713B1 (en) 1987-03-05 2002-06-18 The Liposome Company, Inc. Methods of preparing low-toxicity drug-lipid complexes
US5616334A (en) * 1987-03-05 1997-04-01 The Liposome Company, Inc. Low toxicity drug-lipid systems
WO1988007850A1 (fr) * 1987-04-16 1988-10-20 The Liposome Company, Inc. Procede et appareil pour reduire les dimensions des liposomes en continu
US5030733A (en) * 1987-07-23 1991-07-09 Hoechst-Roussel Pharmaceticals Incorporated Hydroxy-, alkoxy- and benzyloxy-substituted phospholipids
US5145844A (en) * 1987-07-23 1992-09-08 Hoechst-Roussel Pharmaceuticals Incorporated Methods of using hydroxy-, alkoxy- and benzyloxy-substituted phospholipids to treat phospholipase A2 -mediated conditions and to alleviate pain
US4978332A (en) * 1987-09-28 1990-12-18 Matrix Pharmaceutical, Inc. Treatments employing vasoconstrictive substances in combination with cytotoxic agents for introduction into cellular lesion areas
US5185334A (en) * 1989-07-31 1993-02-09 Schering Corporation 2,2-disubstituted glycerol and glycerol-like compounds, compositions and methods of use
US4888328A (en) * 1988-03-10 1989-12-19 Hoeschst-Roussel Incorporated Alkoxycarbonylalkylphospholipids and alkylaminocarbonylalkylphospholipids
US5036152A (en) * 1988-03-10 1991-07-30 Hoechst-Roussel Pharmaceuticals Incorporated Alkoxycarbonylalkylphospholipids and alkylaminocarbonylalkylphospholipids
US5230900A (en) * 1988-07-01 1993-07-27 The Biomembrane Institute Antibody-mediated and ligand-mediated targeting of differentiation-inducers to tumor cells
DE3906952A1 (de) * 1989-03-04 1990-09-06 Boehringer Mannheim Gmbh (3-(c(pfeil abwaerts)1(pfeil abwaerts)(pfeil abwaerts)6(pfeil abwaerts)-c(pfeil abwaerts)1(pfeil abwaerts)(pfeil abwaerts)8(pfeil abwaerts))alkansulfinyl- und sulfonyl-2-methoxymethyl-propyl)-(2-trimethylammonio-ethyl) phosphate, verfahren zu deren herstellung diese verbindungen enthaltende arzneimittel
US5100662A (en) * 1989-08-23 1992-03-31 The Liposome Company, Inc. Steroidal liposomes exhibiting enhanced stability
EP0555229B1 (fr) * 1990-07-31 1996-06-05 The Liposome Company, Inc. Accumulation d'acides amines et de peptides dans des liposomes
WO1992008448A1 (fr) * 1990-11-09 1992-05-29 Cell Technology, Inc. Procede de prevention de myelosuppression due a la radiation ou aux medicaments
US5620703A (en) * 1991-10-11 1997-04-15 Max-Delbruck-Centrum Fur Molekulare Medizin Stimulating hematopoietic activity with carboplatin or lobaplatin
US5817646A (en) * 1991-11-15 1998-10-06 Laboratoires Inocosm Polar lipid composition of plant origin
CN1132586C (zh) 1993-09-09 2003-12-31 罗拉斯医疗公司 来自胆汁的免疫调节组合物、其制备方法及其用途
US6551623B1 (en) 1993-09-09 2003-04-22 Lorus Therapeutics Inc. Immunomodulating compositions from bile
US5707978A (en) * 1994-11-22 1998-01-13 Clarion Pharmaceuticals Inc. Heteroaryl-substituted deoxy glycero-phosphoethanolamines
KR19980703088A (ko) 1995-03-16 1998-09-05 라카일레 지, 필리페 신규의 침전탄산칼슘 안료를 포함하는 잉크젯 기록지
US5834428A (en) * 1995-04-14 1998-11-10 1149336 Ontario Inc. Glucagon-like peptide-2 and its therapeutic use
US5990077A (en) 1995-04-14 1999-11-23 1149336 Ontario Inc. Glucagon-like peptide-2 and its therapeutic use
US6184201B1 (en) 1995-04-14 2001-02-06 Nps Allelix Corp. Intestinotrophic glucagon-like peptide-2 analogs
US5730157A (en) * 1995-12-07 1998-03-24 Clarion Pharmaceuticals Inc. Method for treating viral infection
US5703062A (en) * 1995-12-07 1997-12-30 Clarion Pharmaceuticals Inc. N-het-substituted glycerophosphoethanolamines
US5665714A (en) * 1995-12-07 1997-09-09 Clarion Pharmaceuticals Inc. N-substituted glycerophosphoethanolamines
PT906338E (pt) 1996-04-12 2003-03-31 Ontario Inc 1149336 Analogos do peptido 2 do tipo glucagon
US20040101569A1 (en) * 1996-05-16 2004-05-27 Lorus Therapeutics Inc. Immunomodulating compositions from bile
US6111081A (en) * 1996-05-31 2000-08-29 Baylor College Of Medicine Lactoferrin variants and uses thereof
US5932242A (en) * 1996-10-15 1999-08-03 The Liposome Company, Inc. Ether lipid-containing pharmaceutical compositions and therapeutic uses thereof
US6037125A (en) * 1996-11-05 2000-03-14 Lexicon Genetics Incorporated Disruption of the mammalian RAD51 protein and disruption of proteins that associate with mammalian RAD51 for hindering cell proliferation and/or viability of proliferating cells
US5827836A (en) * 1996-11-15 1998-10-27 Clarion Pharmaceuticals Inc. Retinoid glycerol phospholipid conjugates
CA2236519C (fr) 1997-05-02 2011-09-13 1149336 Ontario Inc. Methodes pour ameliorer le fonctionnement du gros intestin
GB9906695D0 (en) * 1999-03-24 1999-05-19 Secr Defence Vaccine composition
US20020001614A1 (en) * 2000-02-10 2002-01-03 Kent Jorgensen Lipid-based drug delivery systems containing phospholipase A2 degradable lipid derivatives and the therapeutic uses thereof
CA2477979A1 (fr) * 2002-03-05 2003-09-18 Transave, Inc. Systeme d'inhalation pour le traitement d'infections intracellulaires
US7879351B2 (en) * 2002-10-29 2011-02-01 Transave, Inc. High delivery rates for lipid based drug formulations, and methods of treatment thereof
US7718189B2 (en) 2002-10-29 2010-05-18 Transave, Inc. Sustained release of antiinfectives
KR101424980B1 (ko) * 2002-10-29 2014-08-01 인스메드 인코포레이티드 항감염제의 지속적인 방출
US20060078560A1 (en) * 2003-06-23 2006-04-13 Neopharm, Inc. Method of inducing apoptosis and inhibiting cardiolipin synthesis
CA2626049A1 (fr) * 2004-10-15 2006-04-20 Biopharmacopae Design International Inc. Methodes et compositions therapeutiques comprenant des extraits de plantes pour le traitement du cancer
EP1745788A1 (fr) 2005-07-22 2007-01-24 KTB Tumorforschungsgesellschaft mbH Acylglycerophospholipides pour le traitement du cancer et de la cachexie
PT1962805T (pt) 2005-12-08 2016-10-05 Insmed Inc Composições de anti-infeciosos baseadas em lípidos para tratamento de infeções pulmonares
US20100196455A1 (en) 2007-05-04 2010-08-05 Transave, Inc. Compositions of Multicationic Drugs for Reducing Interactions with Polyanionic Biomolecules and Methods of Use Thereof
US9333214B2 (en) 2007-05-07 2016-05-10 Insmed Incorporated Method for treating pulmonary disorders with liposomal amikacin formulations
US9119783B2 (en) 2007-05-07 2015-09-01 Insmed Incorporated Method of treating pulmonary disorders with liposomal amikacin formulations
US9114081B2 (en) 2007-05-07 2015-08-25 Insmed Incorporated Methods of treating pulmonary disorders with liposomal amikacin formulations
US7960336B2 (en) 2007-08-03 2011-06-14 Pharmain Corporation Composition for long-acting peptide analogs
CN101358609A (zh) * 2007-08-03 2009-02-04 富准精密工业(深圳)有限公司 风扇转子
EP2555791B1 (fr) 2010-04-09 2017-11-01 Sinai Health System Méthodes de traitement de troubles du tractus gastro-intestinal au moyen d'un agoniste glp-1
SI2852391T1 (sl) 2012-05-21 2022-04-29 Insmed Incorporated Sistemi za obravnavo pljučnih infekcij
RU2018135921A (ru) 2012-11-29 2019-02-05 Инсмед Инкорпорейтед Стабилизированные составы ванкомицина
KR101951933B1 (ko) * 2013-03-12 2019-02-25 주식회사 아리바이오 라이소포스파티딜콜린 또는 이의 유도체를 포함하는 지질나노물질 및 이의 제조방법
US20160194365A1 (en) 2013-07-08 2016-07-07 The University Of Utah Research Foundation Methods for treatment of and prophylaxis against inflammatory disorders
JP6139781B2 (ja) * 2014-04-04 2017-05-31 国立大学法人大阪大学 リゾリン脂質受容体を活性化する物質を含有する薬剤送達促進剤
DK3142643T3 (da) 2014-05-15 2019-10-14 Insmed Inc Fremgangsmåder til behandling af ikke-tuberkuløse mykobakterielle lungeinfektioner
EP3357512A4 (fr) * 2015-09-29 2019-05-29 Osaka University Promoteur de l'infiltration de leucocytes et immuno-activateur des tumeurs
CZ308596B6 (cs) * 2017-04-03 2020-12-23 Ústav molekulární genetiky AV ČR, v. v. i. Deriváty fosfolipidů a jejich použití jako léčiva
WO2018204918A1 (fr) 2017-05-05 2018-11-08 Ardelyx, Inc. Traitement de troubles hépatiques
JP7460534B2 (ja) 2018-03-30 2024-04-02 インスメッド インコーポレイテッド リポソーム医薬品の連続製造方法
EP3895709A1 (fr) 2020-04-17 2021-10-20 Andreas Hettich GmbH & Co. KG Phospholipide et métabolites de phospholipide destinés au traitement des viraux et des pneumonies bactériennes et de la septicémie

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2081546A1 (fr) * 1970-02-27 1971-12-03 Thomae Gmbh Dr K
FR2081545A1 (fr) * 1970-02-27 1971-12-03 Thomae Gmbh Dr K
FR2364656A1 (fr) * 1976-05-04 1978-04-14 Max Planck Gesellschaft Medicament anti-tumeur a base de compose du type lysolecithine

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2009343C3 (de) * 1970-02-27 1980-10-23 Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V., 3400 Goettingen Verwendung von Lysolecithinen als immunologische Adjuvantien
US4119714A (en) * 1970-02-27 1978-10-10 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E. V. Glycerin-alkylether-(1)-phosphoric acid-(3)-monocholine esters as enhancers of the natural resistance of the mammalian organism against non-carcinogenic pathogens
FR2287901A1 (fr) 1974-10-14 1976-05-14 Pasteur Institut Medicament immunostimulant contenant un derive d'ose ou de polyose phosphoryle
JPS5186117A (en) * 1975-01-27 1976-07-28 Tanabe Seiyaku Co Johoseibiryushiseizainoseiho

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2081546A1 (fr) * 1970-02-27 1971-12-03 Thomae Gmbh Dr K
FR2081545A1 (fr) * 1970-02-27 1971-12-03 Thomae Gmbh Dr K
FR2364656A1 (fr) * 1976-05-04 1978-04-14 Max Planck Gesellschaft Medicament anti-tumeur a base de compose du type lysolecithine

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CA1974 *
CA1976 *
CA1979 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2519864A1 (fr) * 1982-01-20 1983-07-22 Yamanouchi Pharma Co Ltd Composition huileuse a base de medicaments antitumoraux
EP0236487A1 (fr) * 1985-09-17 1987-09-16 Yeda Research And Development Company, Ltd. Inactivation d'un virus
EP0236487A4 (fr) * 1985-09-17 1989-12-28 Yeda Res & Dev Inactivation d'un virus.
EP0370457A1 (fr) * 1988-11-23 1990-05-30 Abbott Laboratories Emulsion de lipides pour traitement du SIDA
WO1994003180A1 (fr) * 1992-07-30 1994-02-17 Prime European Therapeuticals S.P.A. Derives glycerophospho a activite pharmacologique

Also Published As

Publication number Publication date
US4372949A (en) 1983-02-08
GB2046092A (en) 1980-11-12
GB2046092B (en) 1983-11-02
SE8001685L (sv) 1980-10-20
NL8001292A (nl) 1980-09-09
DE3008082A1 (de) 1980-09-18
DE3008082C2 (fr) 1988-02-11
FR2450608B1 (fr) 1984-12-21
IT8048066A0 (it) 1980-03-04
CA1145260A (fr) 1983-04-26
IT1145357B (it) 1986-11-05
SE459228B (sv) 1989-06-19

Similar Documents

Publication Publication Date Title
FR2450608A1 (fr) Agent carcinostatique et immunostimulant contenant un lysophospholipide et un phospholipide et procede pour le preparer
GR3006356T3 (fr)
ES2094479T3 (es) Uso de esteres de l-2-oxotiazolidina-4-carboxilato para la preparacion de un medicamento para estimular la sintesis intracelular de glutation.
ES488120A1 (es) Procedimiento para la preparacion de corticoide-17-alcohil- carbonatos
DK148202C (da) Analogifremgangsmaade til fremstilling af rosmarinsyre-phospholipid-kompleksforbindelser
MY117090A (en) Substituted benzamidines, their preparation and their use as pharmaceutical compounds
CA2047744A1 (fr) Methode de synthese de l'huperzine a et de ses analogues et composes utilises pour ce faire
MX9201908A (es) Metodo para la contracepcion en un primate hembra en edad reproductiva.
AU582757B2 (en) A gangliosides mixture, useful as a therapeutical tool for eliminating painful effects of peripheral neuropathies
BE881225A (fr) Compositions pharmaceutiques consistant en liposomes et procede pour les preparer
MX159192A (es) Una composicion detergente liquida que es suave para la piel
ATE40946T1 (de) Arzneimittel oder prophylaktisches mittel zur behandlung von epilepsie.
PT100415A (pt) Novas morfolinas de accao farmaceutica, e processo para a sua preparacao
FR2374039A1 (fr) Compositions contenant un derive de l'acide salicylique et applications a titre de medicament
ATE175344T1 (de) Gelbildende präparate, die optisch angereicherte gelbildner enthalten
ES2056983T3 (es) Compuestos para inhibir la biosintesis de metabolitos de acido araquidonico derivados de lipoxigenasa.
FR2359153A1 (fr) Nouveaux esters carboxyliques d'acide phosphonoacetique utiles notamment pour le traitement des infections d'herpes simplex
ES2008670B3 (es) Un procedimiento para preparar un derivado del ester guanidinobenzoicoy compuestos farmaceuticos que lo contienen.
KR850008664A (ko) 4-아미노-n-(1-페닐에틸)벤즈아미드의(s)-및(r)-에난티오머의 제조방법
FR2444043A1 (fr) Nouveau derive du paracetamol, son procede de preparation et son utilisation en therapeutique
MX166685B (es) Proceso para la preparacion de alcanosulfonamidas y arenosulfonamidas
ES2084348T3 (es) N-((4,5-dihidroxi- y 4,5,8-trihidroxi-9,10-dihidro-9,10-dioxo-2-antracen-il)carbonil)aminoacidos utiles en la terapia de afecciones osteoarticulares.
IT8148090A0 (it) Soluzioni concentrate stabili di cisplatina utili come composizioni farmaceutiche e relativo procedimento di produzione
IT1210926B (it) Derivati della 1-metil-5-nitro-imidazolina e composizioni terapeutiche che li comprendono come principio attivo.
ES2163001T3 (es) Nuevos derivados de borneol, procedimiento para su preparacion y su utilizacion farmaceutica.

Legal Events

Date Code Title Description
ST Notification of lapse